Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Comment by G1945Von Mar 23, 2021 3:09pm
147 Views
Post# 32859658

RE:RE:RE:RE:RE:Think it reads Satellos gets 60 shares of ICO

RE:RE:RE:RE:RE:Think it reads Satellos gets 60 shares of ICOActually, they will need our vote. The general public owns ~147 Mil + shares, that's about 95% of the common shares outstanding. So management needs shareholder's support and approval. How that will take place and when is the big question. 
 
"The completion of the Arrangement and related transactions is subject to the approval of (i) the Exchange, (ii) 662/3% of the votes cast by iCo and Satellos shareholders, respectively, and (iii) of the Supreme Court of British Columbia."

The terms of the arrangement are not that easy to follow and to understand. I hope they will simplify it at some point. 

G1945V

<< Previous
Bullboard Posts
Next >>